EZH2 and pulmonary fibrosis: Direct or indirect inhibition of MTase EZH2 could therefore lead to a reduction in lung fibrosis and relieve cytokine imbalance, both associated with negative disease outcomes, and thereby contribute to the resolution of acute and long‐term effects of COVID‐19.